UNSPSC 51241133: Dorzolamide hydrochloride

This classification denotes a carbonic anhydrase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QZO5366EW7. European Medicines Agency schedules Dorzolamide hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01820MIG. Dorzolamide hydrochloride generally arises in the molecular formula C10H16N2O4S3.CLH. The term 'dorzolamide hydrochloride' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule dorzolamide hydrochloride under HS 29350090 and SITC 51580. As of Q4 2014, DORZOLAMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dorzolamide hydrochloride bears US NLM identifiers UMLS ID C0771293 and NCI Concept Code C29003. SMILES: CCN[C@H]1C[C@@H](S(=O)(=O)C2C1CC(S2)S(=O)(=O)N)C.CL.

UNSPSC 51241133 Dorzolamide hydrochloride is a Commodity code that encompasses ophthalmologic pharmaceuticals, specifically carbonic anhydrase inhibitors used to treat glaucoma and ocular hypertension. State and local governments procure dorzolamide and similar generic pharmaceuticals through multistate cooperative purchasing vehicles that bundle pharmaceuticals with over-the-counter products into comprehensive supply agreements. The issuing bodies are state procurement offices and multistate cooperative alliances administering shared purchasing arrangements on behalf of participating state agencies, counties, cities, and other public facilities. Vendors supply products through authorized pharmaceutical wholesalers under fixed or net pricing structures, with awards weighted heavily toward price competitiveness, compliance with Good Manufacturing Practices and Drug Supply Chain Security Act requirements, and demonstrated EDI capability.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026, with a March 26, 2026 response deadline to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon. Vendors must maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), submit pricing in fixed-price or net-price formats, maintain comprehensive insurance coverage including $5 million general liability and $2 million network security and privacy liability, and comply with a 3 percent administrative fee. Awards are effective July 1, 2026, with contract terms of two years for new vendors and extensions aligned to June 30, 2028 for incumbents.